CA2664673A1 - Azithromycin for the treatment of nodular acne - Google Patents

Azithromycin for the treatment of nodular acne Download PDF

Info

Publication number
CA2664673A1
CA2664673A1 CA002664673A CA2664673A CA2664673A1 CA 2664673 A1 CA2664673 A1 CA 2664673A1 CA 002664673 A CA002664673 A CA 002664673A CA 2664673 A CA2664673 A CA 2664673A CA 2664673 A1 CA2664673 A1 CA 2664673A1
Authority
CA
Canada
Prior art keywords
azithromycin
acne
treatment
nodules
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002664673A
Other languages
English (en)
French (fr)
Inventor
David Wade Osborne
Gordon Jay Dow
Bhaskar Chaudhuri
Barry Calvarese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Pharmaceutical Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2664673A1 publication Critical patent/CA2664673A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
CA002664673A 2006-10-03 2007-09-24 Azithromycin for the treatment of nodular acne Abandoned CA2664673A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84906506P 2006-10-03 2006-10-03
US60/849,065 2006-10-03
US11/635,127 2006-12-06
US11/635,127 US7704959B2 (en) 2006-10-03 2006-12-06 Azithromycin for the treatment of nodular acne
PCT/US2007/020583 WO2008042139A2 (en) 2006-10-03 2007-09-24 Azithromycin for the treatment of nodular acne

Publications (1)

Publication Number Publication Date
CA2664673A1 true CA2664673A1 (en) 2008-04-10

Family

ID=39261797

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002664673A Abandoned CA2664673A1 (en) 2006-10-03 2007-09-24 Azithromycin for the treatment of nodular acne

Country Status (18)

Country Link
US (2) US7704959B2 (OSRAM)
EP (2) EP2086552B1 (OSRAM)
JP (1) JP2010505827A (OSRAM)
KR (1) KR20090064592A (OSRAM)
CN (2) CN101534837B (OSRAM)
AT (1) ATE533496T1 (OSRAM)
AU (1) AU2007302663B2 (OSRAM)
BR (1) BRPI0719535A2 (OSRAM)
CA (1) CA2664673A1 (OSRAM)
CY (1) CY1112650T1 (OSRAM)
DK (1) DK2086552T3 (OSRAM)
ES (2) ES2574677T3 (OSRAM)
MX (1) MX2009003484A (OSRAM)
PL (2) PL2086552T3 (OSRAM)
PT (1) PT2086552E (OSRAM)
RU (1) RU2009116629A (OSRAM)
SI (1) SI2086552T1 (OSRAM)
WO (1) WO2008042139A2 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143227B2 (en) * 2007-09-05 2012-03-27 Dow Pharmaceutical Sciences, Inc. Azithromycin for treatment of skin disorders
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
CN107281155B (zh) * 2017-06-06 2020-04-10 扬子江药业集团四川海蓉药业有限公司 一种阿奇霉素片及其制备方法
CN111343991A (zh) * 2017-07-21 2020-06-26 阿尔米雷尔有限责任公司 非炎性病变的治疗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474758A (en) 1981-11-19 1984-10-02 American Cyanamid Company Haemophilus influenzae type b and pertussis outer membrane component combined vaccine
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4474766A (en) 1983-06-27 1984-10-02 Merck & Co., Inc. Anti-inflammatory/analgesic combination of cyclo-(N-methyl-Ala-Tyr-D-Trp-Lys-Val-Phe) and a selected non-steroidal anti-inflammatory drug (NSAID)
RO107257B1 (ro) 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
FR2710841B1 (fr) * 1993-10-05 1995-11-17 Oreal Composition cosmétique ou pharmaceutique pour la peau, anhydre et stable, à base de rétinol et son utilisation en vue du traitement des maladies de la peau.
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
WO2002080932A1 (en) * 2001-04-05 2002-10-17 Collagenex Pharmaceuticals, Inc. Methods of treating acne
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
US9035741B2 (en) * 2003-06-27 2015-05-19 Stryker Corporation Foot-operated control console for wirelessly controlling medical devices

Also Published As

Publication number Publication date
DK2086552T3 (da) 2012-01-09
BRPI0719535A2 (pt) 2014-01-14
AU2007302663B2 (en) 2012-07-12
WO2008042139A3 (en) 2008-10-16
CN101534837B (zh) 2012-04-04
EP2086552A2 (en) 2009-08-12
EP2086552B1 (en) 2011-11-16
EP2086552A4 (en) 2009-11-04
SI2086552T1 (sl) 2012-01-31
PL2420240T3 (pl) 2016-10-31
WO2008042139A2 (en) 2008-04-10
HK1130667A1 (en) 2010-01-08
KR20090064592A (ko) 2009-06-19
AU2007302663A1 (en) 2008-04-10
CN102614210A (zh) 2012-08-01
US20100216732A1 (en) 2010-08-26
PL2086552T3 (pl) 2012-03-30
MX2009003484A (es) 2009-10-26
JP2010505827A (ja) 2010-02-25
US7704959B2 (en) 2010-04-27
US20080081790A1 (en) 2008-04-03
PT2086552E (pt) 2011-12-19
RU2009116629A (ru) 2010-11-10
EP2420240A1 (en) 2012-02-22
ES2377470T3 (es) 2012-03-27
ES2574677T3 (es) 2016-06-21
EP2420240B1 (en) 2016-05-11
CN101534837A (zh) 2009-09-16
CY1112650T1 (el) 2016-02-10
ATE533496T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
McLane Analysis of common side effects of isotretinoin
Cunliffe et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle
Suva et al. A brief review on acne vulgaris: pathogenesis, diagnosis and treatment
Goulden Guidelines for the management of acne vulgaris in adolescents
RU2413509C2 (ru) Способ применения адапалена при поддерживающей терапии угревой сыпи
US9132139B2 (en) Maintenance therapy regime/regimen for the treatment of acne
EP1570850A1 (en) Topical formulations for treatment of rosacea
AU2007302663B2 (en) Azithromycin for the treatment of nodular acne
Strauss et al. Concomitant administration of vitamin E does not change the side effects of isotretinoin as used in acne vulgaris: a randomized trial
JP2019524767A (ja) ９−アミノメチルミノサイクリン化合物及びその使用
RU2481832C2 (ru) Применение адапалена и пероксида бензоила для продолжительного лечения угрей обыкновенных
US20050158404A1 (en) Composition and method for treatment of acne
HK1162921A (en) Azithromycin for the treatment of nodular acne
HK1130667B (en) Azithromycin for the treatment of nodular acne
Alyasi et al. Isotretinoin-induced thrombocytosis in a patient with acne vulgaris: a case report
Shalita Isotretinoin in the treatment of acne
JP6951332B2 (ja) 局所用ダプソン組成物を使用して尋常性座瘡を処置する方法
Kreusch et al. Efficacy and tolerability of a topical erythromycin/tretinoin combination preparation in acne treatment: post-marketing surveillance study involving over 6500 patients
Arjel et al. Efficacy of oral azithromycin versus doxycycline in the treatment of acne vulgaris
Abdulwahab et al. The impact of isotretinoin on platelet and white blood cell count in patient with acne vulgaris
Kumar Efficacy of isotretinoin in nodulocystic acne: A clinical and biochemical approach
Statsenko et al. Isotretinoin is the gold standard for acne therapy. Treating severe acne

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140106